Expression of insulin-like growth factor I in the lumbar spinal fusion under control of recombinant human bone morphogenetic protein-2

doi:10.3969/j.issn.2095-4344.2016.08.011

Chinese Journal of Tissue Engineering Research ›› 2016, Vol. 20 ›› Issue (8): 1140-1145.doi: 10.3969/j.issn.2095-4344.2016.08.011

Previous Articles Next Articles

Expression of insulin-like growth factor I in the lumbar spinal fusion under control of recombinant human bone morphogenetic protein-2

Wang Lei-lei¹, Zheng Jun-tao¹, Hu Yong-sheng¹, Liu Wei¹, Liu Xu¹, Jin Ge-le²

¹Third Department of Spinal Surgery, Sixth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China; ²Department of VIP Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China

Received:2015-12-21 Online:2016-02-19 Published:2016-02-19
Contact: Jin Ge-le, Professor, Chief physician, Department of VIP Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China
About author:Wang Lei-lei, Master, Attending physician, Third Department of Spinal Surgery, Sixth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China

Abstract

Abstract:

BACKGROUND: Osteogenic ability of bone morphogenetic protein-2 has been well documented in many experiments, but a series of factors are involved in osteogenesis induction that is a complex network adjustment process.
OBJECTIVE: To quantitatively determine the level of insulin-like growth factor I during the lumbar spinal fusion of rabbits induced by recombinant human bone morphogenetic protein-2.
METHODS: Sixty adult male New Zealand white rabbits were randomly divided into three groups: bone autograft, bone allograft or composite bone (bone allograft with 75 µg recombinant human bone morphogenetic protein-2) was implanted into the L5-6 intertransverse process of rabbits, respectively. At days 7, 14, 21, 28, 35 after implantation, formed callus was taken to detect the expression of insulin-like growth factor I using real-time fluorescence quantitative PCR.
RESULTS AND CONCLUSION: In the three groups, the expression of insulin-like growth factor I gradually increased with implantation time, peaked at 28 days and then decreased. At 7 days after implantation, the expression of insulin-like growth factor I was higher in the autograft group than the composite and allograft groups (P < 0.05); at 14 days, the expression of insulin-like growth factor I was higher in the autograft and composite groups than the allograft group (P < 0.05); at 21, 28 and 35 days, the expression of insulin-like growth factor I was higher in the composite group than the autograft and allograft groups (P < 0.05). These findings indicate that recombinant human bone morphogenetic protein-2 can improve the expression of insulin-like growth factor I effectively during the lumbar spinal fusion.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Wang Lei-lei, Zheng Jun-tao, Hu Yong-sheng, Liu Wei, Liu Xu, Jin Ge-le. Expression of insulin-like growth factor I in the lumbar spinal fusion under control of recombinant human bone morphogenetic protein-2[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(8): 1140-1145.

Figures/Tables 2

References

[1] Berglund JD,Galis ZS.Designer blood vessels and therapeutic revascularization.Br J Pharmacol.2003; 140: 627-636.

[2] L'Heureux N,Dusserre N,Marini A,et al.Technology insight: the evolution of tissue-engineered vascular grafts from research to clinical practice.Nat Clin Pract Cardiovasc Med.2007;4(7):389-395.

[3] Schmedlen RH,Elbjeirami WM,Gobin AS,et al.Tissue engineered small diameter vascular grafts.Clin Plas Surg.2003;30:507-517.

[4] Walpoth BH,Bowlin GL.The daunting quest for a small diameter vascular graft. Expert Rev Med Devices. 2005;2:647-651.

[5] Cowan CM,Soo C,Ting K,et al.Evolving concepts in bone tissue engineering.Curr Top Dev Biol. 2005;66:239-285.

[6] 王磊磊,金格勒,任龙龙,等.不同植骨材料在腰椎融合过程中的应用及转化生长因子β的表达[J].中国组织工程研究, 2011,15(16):2885-2888.

[7] The Ministry of Science and Technology of the People’s Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.

[8] Keating JF, McQueen MM. Substitutes for autologous bone graft in orthopaedic trauma. J Bone Joint Surg Br. 2001;83(1):3-8.

[9] okamoto MJ,Murai JJ,Ybshikawa HJ,et al.Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.J Bone Miner Res. 2006;2l(7):1022-1033．

[10] 韩昕光,毕郑钢,王东奎,等.骨不连接区成骨活性的实验研究[J].中华创伤骨科杂志,2009,11(1):45-50．

[11] Heggebo J,Haasters F,Polzer H,et al.Aged human mesenchymal stem cells：the duration of bone morphogenetic proten-2 stimulation determines induction or inhibition of osteogenic differentiation. Orthop Rev.2014;6(2):5242.

[12] Prall WC, Haasters F, Heggebo J, et al．Mesenchymal stem cells from osteoporotic patients feature impaired signal transduction but sustained osteo -induction in response to BMP-2 stimulation．Biochem Biophys Res Cormun, 2013, 440(9): 617-622．

[13] 方秀统．BMP-2和VEGF-165双基因共转染大鼠骨髓基质干细胞体内成骨的实验研究[D].长春:吉林大学, 2006．

[14] Razzouk S, Sarkis R. BMP-2: biological challenges to its clinical use. N Y State Dent J. 2012;78(5): 37-39．

[15] 王磊,章燕,游素兰,等.骨形态发生蛋白一2与碱性成纤维细胞生长因子在异位和原位成骨中的作用[J].华西口腔医学杂志, 2012,30(4):420-424．

[16] Ramakers C, Ruijter JM, Dep rez RH, et al. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data . Neurosci Lett. 2003; 339(1): 62-66.

[17] Kurland ES,Rosen CJ,Cosman F,et al.Insulin-like growth factor-I in men with idiopathic osteoporosis.Clin Endocrinol Metab.1997;82:2799.

[18] Mauras N,Doi SQ,Shapiro JR.Recombinant human in-sulin like growth factor-1,recombinant human growth hormone,andsex steroids:effects on markers of bone turnover in humans.J Clin Endocrinol Metabol. 1996; 81 (6): 2222-2226.

[19] Rosen CJ.Insulin-like growth factor system and bone.Current Opin-ion in Endocrinology. Diabetes. 2001;8(6):277-282.

[20] 唐周舟,金格勒,李忠伟,等.重组人骨形态发生蛋白-2/异体骨复合骨用于兔腰椎融合的显微CT研究[J].中华实验外科杂志, 2009,30(11):2816-2825.

[21] Glassman SD,Dimar JR,Carreon L Y,et al.Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcuim phosphate/collagen carrier in postlateral spine fusion. Spine. 2005;30: 1694-1698.

[22] Burkus JK,Sandhu HS,Cornet MF,et al.Use of rhBMP-2 in combination with structural cortical allografts:Clinical and radiographic outcomes in anterior lumbar spinal surgery.J Bone Joint Surg Am.2005;87:1205-1212.

[23] Rey-Rico A,Silva M,Couceiro J,et al.Osteogenic efficiency of in situ gelling poloxamine systems with and without bone morphogenetic protein-2.Eur Cell Mater.2011;21:317-340.

[24] Ikeuchi M, Dohi Y, Horiuchi K,et al. Recombinant human bone morphogenetic protein-2 promotes osteogenesis within atelopeptide type I collagen solution by combination with rat cultured marrow cells.J Biomed Mater Res.2002;60(1):61-69.

[25] Vaidya R,Weir R,Sethi A,et al.Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence.J Bone Joint Surg Br.2007;89(3):34.

Expression of insulin-like growth factor I in the lumbar spinal fusion under control of recombinant human bone morphogenetic protein-2

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References

Related Articles 0

Recommended Articles

Metrics

Comments